Standout Papers

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with... 2017 2026 2020 2023 379
  1. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer (2017)
    Stephen Bagley, Shawn Kothari et al. Lung Cancer

Immediate Impact

2 by Nobel laureates 3 from Science/Nature 69 standout
Sub-graph 1 of 23

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
2 intermediate papers

Works of Faith Mutale being referenced

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer
2019
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
2017 Standout

Author Peers

Author Last Decade Papers Cites
Faith Mutale 563 312 86 107 10 784
Brian W. Goodell 319 245 80 123 12 928
Maria Olsen 315 108 92 90 20 896
Howard I. Scher 472 330 114 54 16 944
Vittorio Mattioli 371 227 47 34 21 731
Dinorah Martinez‐Tyson 431 208 94 31 19 969
Gerald E. Metter 392 156 113 28 21 764
Yali Fu 350 335 61 19 15 974
Cynthia Harris 291 207 46 25 16 742
R Cox 331 206 76 44 10 792
Paul Blood 247 269 126 77 33 662

All Works

Loading papers...

Rankless by CCL
2026